Diversity in Clinical Trials: Challenges and Opportunities for Ibero-American Countries
Authors
-
Nelson Santiago Vispo
Clinical Biotec SL. and Bionatura Journal. Madrid. 28029. Spain
https://orcid.org/0000-0002-4081-3984
DOI:
https://doi.org/10.70099/BJ/2024.01.04.1Keywords:
Clinical trials, Ibero-American population, pharmacogenomics, genetic diversity, personalized medicine, inclusion, health equity, RIBEF, sociocultural factors, medical researchAbstract
The Ibero-American population faces significant challenges in participating in international medical advancements, particularly in clinical trials. The Ibero-American population faces significant challenges in participating in international medical advancements, particularly in clinical trials. The enhancement of diversity in these studies is imperative for the development of safer and more efficacious treatments that are tailored to the distinctive genetic, cultural, and socioeconomic characteristics of the region. A lack of representation perpetuates healthcare inequalities and undermines scientific validity of findings. Research from organizations like Red Iberoamericana de farmacogenética y Farmacogenómica (RIBEF), which advocates for ethnic diversity in pharmacogenomics, shows how important personalized medicine is. Reforms to the participant selection criteria and collaborative approaches with local institutions are essential to ensure health equity and enhance overall well-being in Ibero-America.
References
1. Ramos TI, Castro KA, Escalante LS, Vispo NS. Advances in Clinical Research in Ecuador. Ther Innov Regul Sci. 2017 May;51(3):307–13.
2. Communications. Integra IT. 2024 [cited 2024 Nov 9]. Por qué importa la diversidad en los ensayos clínicos. Available from: https://www.integrait.co/es/por-que-importa-la-diversidad-en-los-ensayos-clinicos/
3. Kalman L, Agúndez J, Appell ML, Black J, Bell G, Boukouvala S, et al. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin Pharma and Therapeutics. 2016 Feb;99(2):172–85.
4. Fatumo S, Chikowore T, Choudhury A, Ayub M, Kuchenbäcker K. A Roadmap to Increase Diversity in Genomic Studies.
5. Abraham J. International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. In: Tietje C, Brouder A, editors. Handbook of Transnational Economic Governance Regimes [Internet]. Brill | Nijhoff; 2010 [cited 2024 Nov 8]. p. 1041–53. Available from: https://brill.com/view/book/edcoll/9789004181564/Bej.9789004163300.i-1081_085.xml
6. Desafíos en la representación étnica en ensayos clínicos: Hacia una mayor equidad en la investigación médica | Medby [Internet]. 2024 [cited 2024 Nov 24]. Available from: https://medby.org/desafios-en-la-representacion-etnica-en-ensayos-clinicos-hacia-una-mayor-equidad-en-la-investigacion-medica/
7. Taparra K, Benavente R, Shih JJ, Gimmen MY, Tominez P, Kekumano K, et al. Race and Ethnicity Representation in Phase 2/3 Oncology Clinical Trial Publications: A Systematic Review. JAMA Health Forum. 2024 Jun 7;5(6):e241388.
8. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023 Sep 22;23(1):689.
9. Michos ED, Reddy TK, Gulati M, Brewer LC, Bond RM, Velarde GP, et al. Improving the enrollment of women and racially/ethnically diverse populations in cardiovascular clinical trials: An ASPC practice statement. American Journal of Preventive Cardiology. 2021 Dec 1;8:100250.
10. Peñas-LLedó E, Terán E, Sosa-Macías M, Galaviz-Hernández C, Gil JP, Nair S, et al. Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting. Clinical Therapeutics. 2020 Aug 1;42(8):1595-1610.e5.
11. Rodrigues-Soares F, Peñas-Lledó EM, Tarazona-Santos E, Sosa-Macías M, Terán E, López-López M, et al. Genomic Ancestry, 2D6, 2C9, and 2C19 Among Latin Americans. Clinical Pharmacology & Therapeutics. 2020;107(1):257–68.
12. LLerena A, Naranjo MEG, Rodrigues-Soares F, Penas-LLedó EM, Fariñas H, Tarazona-Santos E. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opinion on Drug Metabolism & Toxicology. 2014 Nov;10(11):1569–83.
13. Salas-Hernández A, Galleguillos M, Carrasco M, López-Cortés A, Redal MA, Fonseca-Mendoza D, et al. An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean. Front Pharmacol. 2023 May 11;14:1175737.
14. Gallego-Perez D, Wardle J, Declercq E, Wirtz V, Saper R, Barnes L. Therapeutic pluralism policies in latin america: advances, gaps, and opportunities towards inclusive, people-centered health care systems. Popul Med [Internet]. 2023 Apr 26 [cited 2024 Nov 9];5(Supplement). Available from: http://www.populationmedicine.eu/Therapeutic-pluralism-policies-in-latin-america-advances-gaps-and-opportunities-towards,164473,0,2.html
15. Bonilla CE, Montenegro P, O’Connor JM, Hernando-Requejo O, Aranda E, Pinto Llerena J, et al. Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer. Cancers. 2023 Sep 1;15(17):4373.
16. Principi N, Petropulacos K, Esposito S. Impact of Pharmacogenomics in Clinical Practice. Pharmaceuticals. 2023 Nov 13;16(11):1596.
17. Diaz-Horta O, Cintado A, Fernandez-De-Cossio ME, Nazabal M, Ferrer A, Roca J, et al. Relationship of type 1 diabetes to ancestral proportions and HLA DR/DQ alleles in a sample of the admixed Cuban population. Annals of Human Biology. 2010 Nov;37(6):778–88.
18. Guevara M, Rodrigues-Soares F, De La Cruz CG, De Andrés F, Rodríguez E, Peñas-Lledó E, et al. Afro-Latin American Pharmacogenetics of CYP2D6, CYP2C9, and CYP2C19 in Dominicans: A Study from the RIBEF-CEIBA Consortium. Pharmaceutics. 2024 Oct 30;16(11):1399.
19. Red Ribef [Internet]. [cited 2024 Nov 10]. Inicio. Available from: https://redribef.org
20. Number of clinical trials by year, location, disease, phase, age and sex of trial participants [Internet]. [cited 2024 Nov 24]. Available from: https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-trial-registrations-by-year-location-disease-and-phase-of-development-feb-2022
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with BioNatura Journal agree to the following terms: Authors retain copyright and grant the BioNatura Institutional Publishing Consortium (BIPC) right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). This allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
